Previous Article | Next Article 
Journal of Virology, July 2000, p. 5819-5824, Vol. 74, No. 13
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
The E4-6/7 Protein Functionally Compensates for the
Loss of E1A Expression in Adenovirus Infection
Robert J.
O'Connor
and
Patrick
Hearing*
Department of Molecular Genetics and
Microbiology, School of Medicine, State University of New York,
Stony Brook, New York 11794
Received 11 October 1999/Accepted 6 April 2000
 |
ABSTRACT |
The E1A gene products are required and sufficient for activation of
adenovirus gene expression in cultured cells. The E4-6/7 gene product
induces the binding of the cellular transcription factor E2F to the
viral E2a promoter region. The induction of E2F binding to the E2a
promoter in vitro is directly correlated with transcriptional
activation of the E2a promoter in vivo. The E2 region encodes the viral
replication proteins, yet adenoviruses lacking E4-6/7 function
demonstrate no defective phenotype in infected cells. Here we show that
the E4-6/7 protein can functionally compensate for E1A expression in
virus infection. In the absence of the E1A gene products, expression of
the E4-6/7 protein is sufficient to displace retinoblastoma protein
family members from E2Fs, activate expression of early region 2 via
induction of E2F DNA binding to the E2a promoter region, and
significantly enhance replication of an E1A-defective adenovirus. These
results have implications in the regulation of viral gene expression
and for the development of recombinant adenovirus vectors.
 |
INTRODUCTION |
Adenovirus (Ad) early gene
expression is regulated by several viral gene products. E1A is the
first transcription unit expressed during Ad infection, and the E1A
proteins activate viral and cellular gene expression by multiple,
independent mechanisms (8). Both the E1A 12S and 13S gene
products bind to members of the retinoblastoma (Rb) protein tumor
suppressor family (pRb, p107, and p130) (6). Among numerous
cell binding partners, members of the Rb protein family interact with
and repress the activity of members of the E2F transcription factor
family (6). Sequestration of Rb protein family members by
the E1A proteins releases free E2F, which transactivates both viral and
cellular promoter regions containing E2F-responsive promoter elements.
The E1A 13S gene product also transactivates viral and cellular
promoters by different mechanisms involving interaction with cellular
transcription factors such as the TATA binding protein, the
activating transcription factor, and the suppressor of RNA polymerase B
(SRB) mediator complex (2, 18, 19). The net effect of E1A
gene expression early after infection is a significant increase in the
activity of the other early Ad promoter regions. As expected, E1A
mutants have dramatically reduced viral gene expression and,
consequently, productive virus infection (16).
E2F was first described as a nuclear activity that bound to an inverted
repeat in the Ad type 5 (Ad5) E2a promoter (17). The binding
activity of E2F to these sites is stimulated by Ad infection dependent
on the activities of two viral proteins. E2F transcriptional activity
is positively regulated by the Ad E1A gene products, which dissociate
Rb protein family members from E2Fs (4). Free E2F is then
bound by the Ad E4-6/7 protein, which forms a complex with E2F and
induces the cooperative and stable binding of E2F to the inverted
binding sites in the Ad5 E2a promoter (12, 13, 15, 22, 30).
The induction of E2F binding to the Ad5 E2a promoter in vitro is
directly correlated with transcriptional activation of the E2a promoter
as assayed using transient-expression assays and virus infection assays
in vivo (24, 25, 26, 27, 32).
Ads lacking E4-6/7 function demonstrate no defective phenotype in the
presence of the E1A gene products (11). Yet Ads of different
serotypes encode E4-6/7 gene products capable of induction of E2F DNA
binding activity and transactivation of promoter regions carrying
inverted E2F binding sites (33). Further, the integrity of
the E2F binding sites is important for E2a promoter activity in the
context of Ad infection (21). The function of the E4-6/7 protein may be masked by or auxiliary to E1A during Ad infection of
cultured cells. A role for the E4-6/7 protein cannot readily be
addressed using viruses lacking the E1A transcription unit, since E1A
proteins are required to express the E4 gene products. To ask if E4-6/7
could contribute to viral growth in the absence of the E1A proteins,
wild-type E4-6/7 under control of the cytomegalovirus (CMV)
promoter/enhancer was introduced in place of the E1A coding region in a
virus background carrying a deletion that disrupts E4-6/7 activity
(11). In the absence of the E1A gene products, we found that
expression of the E4-6/7 protein was sufficient to displace Rb protein
family members from E2Fs, activate expression of early region 2 via the
induction of E2F DNA binding to the E2a promoter region, and
significantly enhance replication of an E1A-defective Ad. These results
suggest that the E1A and E4-6/7 proteins exhibit redundant functions
for activation of the viral E2a promoter. Additionally, Ads that
express all or part of early region 4 are being developed as gene
therapy vectors for enhanced transgene expression (1, 3, 9, 20,
29, 37). The results presented here have important implications
for the use of recombinant Ad vectors, since viruses that are deemed to
be replication defective due to E1A deletion may in fact replicate and
exhibit viability due to E4-6/7 protein expression.
 |
MATERIALS AND METHODS |
Viruses and infections.
Monolayer cultures of HeLa and A549
cells were maintained in Dulbecco's modified minimal essential medium
containing 10% calf serum (HyClone); monolayer cultures of human
embryonic lung (HEL) cells were maintained in Dulbecco's modified
minimal essential medium containing 10% fetal bovine serum. Ad5
viruses WT300 and dl356 were described previously
(11). dl356 contains a 2-bp deletion in E4 open
reading frame 7 (ORF7) which disrupts the reading frame downstream of
amino acid 91 and leads to expression of a truncated, nonfunctional
E4-6/7 product. Ad-CMV-6/7-WT and Ad-CMV-6/7-F125P were constructed by
inserting cDNAs corresponding to the Ad2 wild-type E4-6/7 protein or
E4-6/7 mutant F125P (26) adjacent to the CMV
promoter/enhancer in a plasmid containing the left 1,339 nucleotides
(nt) of Ad5 (deletion of Ad5 nt 355 to 811). The E2-LS-CAT virus
contains the XhoI-to-XbaI fragment of
pE2a-E-CAT-LS-74/-85 (23) in place of the E1A region (nt 355 to 811). These plasmids were rebuilt into a dl356 virus
background by the method of Stow (35) and propagated using
293 cells, an E1 complementing cell line (10). Recombinant
viruses were plaque purified, virus stocks were amplified, and purified
virus particles were prepared by CsCl equilibrium centrifugation
following standard approaches (38). Virus particles were
quantified by lysis of dilutions in buffer containing 0.1% sodium
dodecyl sulfate (SDS) and absorbance at 260 nm was measured; 1 optical
density unit at 260 nm equals 1012 particles/ml.
For viral growth curves, monolayer cultures of HeLa, A549, and HEL
cells were grown to 75% confluency and infected with viruses at 100 particles per cell (corresponding to approximately 4 to 5 infectious
viruses per cell) for 1 h at 37°C. The cell monolayers were then
washed with phosphate-buffered saline solution, and fresh medium was
added. Total cell lysates were prepared at different times after
infection by freeze-thawing of infected cells in culture medium, and
the virus yield was measured by serial dilution of infected cell
lysates and plaque assay on 293 cells. Particle-PFU ratios were
determined by serial dilution of purified virus particles and plaque
assay on 293 cells.
Protein and DNA analyses.
For viral protein expression
analyses, monolayer cultures of HeLa cells were grown to 75%
confluency and infected with viruses at 200 particles per cell for
1 h at 37°C. At different times after infection, infected cells
were washed with phosphate-buffered saline and harvested. Cell pellets
were resuspended in SDS-lysis buffer (14), boiled, and
sonicated, and the insoluble debris was removed by centrifugation at
12,000 × g for 15 min. For immunoprecipitation and
Western blot analysis of E4-6/7 proteins, cleared cellular lysates were
immunoprecipitated using anti-E4-6/7 monoclonal antibody M80 (MAb M80)
(26), and the immune precipitates were analyzed by Western
blotting using MAb M80 as the primary antibody. DNA-binding protein
(DBP) expression was analyzed directly using cellular extracts by
Western blotting with an anti-DBP monoclonal antibody (MAb 72-10)
(31). Proteins were detected by enhanced chemiluminescence using ECL detection reagents (Amersham).
Viral DNA was isolated from purified particles by lysis with 0.1% SDS
and proteinase K digestion. Following phenol-chloroform
extraction and
ethanol precipitation, DNA preparations were digested
with
XbaI to distinguish between the left-end fragments of
different
viral DNAs. Viral DNAs were analyzed by Southern blot
hybridization
using a fragment corresponding to the left 355 bp of Ad5
DNA,
32P labeled by the random primer method
(
7), as a
probe.
Nuclear extract preparation and gel mobility shift assays.
Nuclear extracts were prepared according to the method of Dignam et al.
(5). Nuclear fractions were dialyzed against dialysis buffer
(DB; 20 mM HEPES [pH 7.5], 100 mM KCl, 10% glycerol, 5 mM
MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, 0.5 mM
phenylmethylsulfonyl fluoride), and the dialysate was cleared by
centrifugation at 25,000 × g. In vitro DNA binding
assays were essentially performed as described previously (26,
27). Briefly, binding reaction mixtures (20 µl) contained 5 to
10 µg of nuclear extract, 2 µg of sonicated salmon sperm DNA, and
20,000 cpm of 32P-labeled Ad5 E2a promoter region probe DNA
(1 to 2 fmol of DNA) in DB supplemented with Nonidet P-40 (final
concentration, 0.1%). Binding reactions were performed for 1 h at room
temperature, and then the products were electrophoresed in a 4%
polyacrylamide nondenaturing gel at 4°C. The E2F double-site probe
contains nt
30 to
73 from the E2a promoter plus additional vector
sequences. Antibodies used for supershift analyses were anti-Rb (MAb
C36) (Oncogene Science), anti-p107 (MAb SD9) (Santa Cruz
Biotechnology), and anti-
E4-6/7 (MAb M45) (26).
 |
RESULTS |
The function of the E4-6/7 protein during viral infection may be
masked by or is auxiliary to E1A during Ad infection of cultured cells.
A role for the E4-6/7 protein cannot readily be addressed using viruses
lacking the E1A transcription unit, since E1A proteins are required to
express the E4 gene products (8). To determine if E4-6/7
could contribute to viral growth in the absence of the E1A proteins,
wild-type E4-6/7 under the control of the CMV promoter/enhancer was
introduced in place of the E1A coding region in a virus background carrying a deletion that disrupts E4-6/7 activity (mutant virus dl356) (11). dl356 contains a 2-bp
deletion in E4 ORF7 which disrupts the reading frame downstream of
amino acid 91 and leads to expression of a truncated, nonfunctional
E4-6/7 product. An E4-6/7 mutant (F125P) that binds E2F efficiently but
contains a mutation that eliminates E4-6/7 dimerization, and thus the
induction of E2F DNA binding to the inverted binding sites in the viral E2a promoter (26), was separately introduced into the same
mutant virus background. These viruses, dl356+E4-6/7-WT
and dl356+E4-6/7-F125P (Fig.
1A), expressed similar levels of E4-6/7
protein as wild-type Ad (WT300) in infected HeLa cells (Fig. 1B).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Structural organization of recombinant Ads. The Ad
genome is represented by a bold line. Mutant viruses described in the
text are shown with the early proteins expressed (indicated with
arrows). (B) E4-6/7 protein expression with recombinant adenoviruses.
HeLa cells were infected at a multiplicity of infection of 100 virus
particles per cell. Total cellular extracts were prepared 16 h
after infection, and E4-6/7 proteins were immunoprecipitated and
analyzed by Western blotting using MAb M80 (26). The Ad5
E4-6/7 protein migrates with faster mobility than the Ad2 E4-6/7
proteins produced by the recombinant viruses. The extracts were
prepared from cells infected with the indicated viruses.
|
|
The ability of these recombinant viruses to undergo a lytic infection
in HeLa cervical carcinoma cells was analyzed by a one-step growth
curve. A virus that lacks the E1A coding region and carries the
dl356 E4-6/7 mutation was used as a negative control (the E1
region was replaced by a chloramphenicol acetyltransferase [CAT]
expression cassette; dl356+CAT) (28), and the
E4-6/7 mutant virus, dl356, was tested as the parent of
these recombinant viruses. Input virus was quantified at 6 h after
infection and virus production was quantified at 1, 2, and 3 days after
HeLa cell infection by a plaque assay using the E1 complementing cell
line 293 (Fig. 2). As previously reported
(11), mutation of the E4-6/7 reading frame in an otherwise
wild-type Ad background (dl356) did not reduce virus growth
in comparison to wild-type Ad5 (WT300). Deletion of the E1A region in a
dl356 mutant background (dl356+CAT) reduced virus growth by more than 4 orders of magnitude, consistent with previous analyses of the growth of E1A mutant viruses (16). Surprisingly, constitutive expression of wild-type E4-6/7 in the absence of E1A (dl356+E4-6/7-WT) in part rescued the E1A
defect. Levels of this recombinant virus were 50-fold lower than levels of WT300, an increase of 500-fold in comparison to the E1A/E4-6/7 double mutant virus, dl356+CAT. In contrast, a virus
expressing the E4-6/7 protein deficient for E2F induction
(dl356+E4-6/7-F125P) was increased only 10-fold in
comparison to the E1A/E4-6/7 double mutant. The increase in growth of
mutant dl356+E4-6/7-F125P in comparison to the E1A/E4-6/7
double mutant may reflect a limited activation of viral early gene
expression by the CMV enhancer/promoter in the
dl356+E4-6/7-F125P genome and/or the activation of E2F transcription factors by displacement of Rb protein family binding proteins (see Discussion). These results demonstrate that the E4-6/7
protein can contribute to viral growth in proliferating cultured cells
in the absence of E1A expression.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 2.
E1A-independent growth of Ad in HeLa cells. HeLa cells
were infected at a multiplicity of infection of 100 virus
particles per cell (~4 to 5 PFU/cell), and cellular lysates were
prepared at 6 h and 1, 2, and 3 days after infection. Virus
production was quantified by plaque assay using 293 cells to complement
the E1A defect with the recombinant viruses. The results are presented
as log virus yield for each data point and represent the results of
three independent experiments. The viruses used in the analysis are
depicted in Fig. 1A.
|
|
HeLa cells contain and express human papillovirus (HPV) DNA
(34) and the E6 and E7 regulatory proteins that affect the
p53 and pRb regulatory pathways (36). These functions are
similar to those performed by Ad E1A and E1B 55-kDa proteins
(6). To determine if HPV protein expression contributed to
the growth of E1A-negative, E4-6/7-expressing recombinant Ad vectors,
the growth properties of these viruses were analyzed in the human lung
carcinoma cell line A549, which lacks endogenous HPV sequences, as well
as in primary human HEL cells. The results of these analyses (Fig.
3A and B, respectively) were nearly
indistinguishable from those obtained with HeLa cells. The recombinant
virus that constitutively expressed wild-type E4-6/7 in the absence of
E1A (dl356+E4-6/7-WT) was reduced 50-fold in yield in A549
cells and 100-fold in yield in primary HEL cells in comparison to
WT300. In contrast, growth of a virus expressing the E4-6/7 protein
deficient for E2F induction (dl356+E4-6/7-F125P) was
increased only fivefold in A549 cells and less than twofold in HEL
cells in comparison to that of the E1A/E4-6/7 double mutant
dl356+CAT. These results confirm the interpretation made
from experiments with HeLa cells that the E4-6/7 protein can complement
the absence of the E1A gene expression in virus growth assays.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 3.
E1A-independent growth of Ad in A549 (A) and HEL (B)
cells. A549 and HEL cells were infected at a multiplicity of infection
of 100 virus particles per cell (~4 to 5 PFU/cell), and cellular
lysates were prepared at 6 h and 1 and 2 days after infection.
Virus production was quantified as described in the legend to Fig. 2.
Symbols: , WT300; , dl356; *, dl356+E4-6/7-WT; ,
dl356+E4-6/7-F125P; ×, dl356+CAT.
|
|
As further controls for these studies, the purity of the virus stocks
was analyzed and the physical virus particle-to-infectious virus
particle ratios (particle/PFU ratios) were determined. Figure 4 shows a Southern blot analysis of viral
DNA isolated from the purified virus particle stocks used for these
analyses. Distinct left-end DNA restriction fragments corresponding to
the different viral genomes were observed, and no evidence of
contamination of recombinant viruses with wild-type Ad was seen. The
corresponding right-end fragment common to all of the viruses under
study serves as an internal control for comparable DNA loading in this
analysis. If the particle/PFU ratios of the recombinant Ads were
significantly lower than those of the wild-type Ad5, then the growth
properties of such viruses may be artificially increased due to a
greater input of these viruses than of the wild type. While the 6-h
time points in the growth curves did not indicate this to be the case, the results shown in Table 1 demonstrate
that all viruses exhibited typical particle/PFU ratios for Ad5 (ranging
from 14:1 to 33:1). We conclude that the growth properties of viruses
that constitutively express the E4-6/7 protein do not reflect
abnormalities in the virus stocks used for the studies.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 4.
Analysis of recombinant Ad DNAs. Viral DNAs from
purified virions were isolated, digested with XbaI, and
analyzed by Southern blotting using an Ad5 left-end radiolabeled probe
(nt 1 to 355). The individual left-end DNA fragments of the different
viruses and the common right-end fragment found with all viruses are
indicated. The viral DNAs used in this analysis are indicated at the
top of each lane.
|
|
It is surprising that replacement of E1A with an E4-6/7 expression
cassette would only cause a moderate defect in viral growth, since the
E4-6/7 protein may not be sufficient to induce high levels of the E2
gene products required for viral DNA replication and since other early
transcription units such as E4 would not be expected to be expressed.
Since the E1A gene products normally are required in virus infection to
liberate free E2F activity from repression by Rb protein family members
to allow E2F to serve as a target for E4-6/7 binding, we analyzed
E2F-specific complexes found after infection with the different
recombinant viruses using a gel mobility shift assay with a
radiolabeled probe corresponding to the inverted E2F sites of the Ad5
E2a promoter (Fig. 5). Different E2F
binding complexes corresponding to both free E2F activity and E2F in
complexes with pRb and p107 were observed using a nuclear extract from
uninfected HeLa cells (Fig. 5, lane 1). The identification of
higher-order E2F complexes is well documented in the literature and was
confirmed using specific antibodies to E2F binding partners (pRb and
p107) (Fig. 5, lanes 7 through 9). Infection with wild-type Ad5 (lane
2) resulted in the disappearance of E2F-Rb and E2F-p107 complexes due
to E1A expression and the appearance of induced E2F activity containing
the E4-6/7 protein. The loss of E2F-Rb and E2F-p107 complexes is
evident visually and was confirmed using specific antibodies (lanes 10 through 13) where no change in binding pattern was seen in contrast to
that observed with the antibodies and uninfected HeLa nuclear extract
(lanes 7 through 9). E1A expression in the absence of E4-6/7 (E1+/E4
and dl356) (Fig. 5, lane 2) resulted in predominantly free
E2F binding activity, while the absence of both the E1A and E4-6/7 gene
products (E1
/E4
and dl356+CAT) (lane 5) yielded E2F
complexes that were equivalent to uninfected HeLa nuclear extract. Note
that expression of wild-type E4-6/7 in the absence of E1A (E1
/E4+ and
dl356+E4-6/7-WT) (lane 4) gave rise to a binding pattern
nearly identical to that found in the case of wild-type Ad5 (lane 2).
That the major induced E2F complex with dl356+E4-6/7-WT
contained the E4-6/7 protein was confirmed by using a monoclonal
antibody against this product (26) (compare lanes 11 and
15). The minor new binding activity that was evident just above the
free E2F activities corresponds to an E2F-E4-6/7 monomeric complex and
also was recognized by the E4-6/7 antibody (lane 15). Additionally,
expression of the E4-6/7 protein in the absence of E1A disrupted
E2F-pRb and E2F-p107 complexes, since no evidence of these higher-order
E2F complexes was observed when specific antibodies were used (compare
lanes 12 and 13 to 16 and 17). Thus, expression of E4-6/7 in the
absence of E1A displaced Rb protein family members from E2F and gave
rise to induction of E2F activity in a manner identical to that
observed with wild-type Ad.

View larger version (71K):
[in this window]
[in a new window]
|
FIG. 5.
E2F complexes present in HeLa cells infected with
recombinant viruses. HeLa cells were infected at a multiplicity of
infection of 200 virus particles per cell (~8 to 10 PFU/cell), and
nuclear extracts were prepared 6 h after infection as previously
described (20). E2F binding activities were assessed using a
gel mobility shift assay with a radiolabeled probe corresponding to the
E2F sites in the Ad5 E2a promoter region, as previously described
(5). Cellular E2F complexes are indicated by arrows on the
left, and the Ad-induced E2F complex is indicated on the right. The
viruses used in the analysis are depicted in Fig. 1A and are indicated
in the figure as WT300 (wild-type Ad5), E1+/E4 (dl356),
E1 /E4-WT (dl356+E4-6/7-WT), E1 /E4
(dl356+CAT), and E1 /E4-F125P
(dl356+E4-6/7-F125P). The antibodies used were anti-Rb (MAb
C36) (Oncogene Science), anti-p107 (MAb SD9) (Santa Cruz
Biotechnology), and anti-E4-6/7 (MAb M45) (26). Uninf.:
uninfected.
|
|
The simplest explanation for the efficient growth of recombinant virus
dl356+E4-6/7-WT is that expression of the viral replication machinery encoded by the E2 transcription unit is an important rate-limiting event for a productive infection of cells in culture. To
examine whether the growth properties of the different recombinant viruses were due to their level of E2 gene expression, accumulation of
the E2 72-kDa DBP was measured by immunoblot analysis (31) following infection of HeLa cells. Protein lysates were prepared 8, 16, and 24 h after infection by wild-type Ad5 (WT300),
dl356+E4-6/7-WT, and dl356-E4-6/7-F125P. As shown
in Fig. 6, DBP expression levels with
these viruses correlated very well with their growth properties in HeLa
cells, where significant accumulation of DBP was evident with
dl356+E4-6/7-WT in comparison to accumulation of wild-type Ad5, and no evidence of DBP expression was seen with
dl356+E4-6/7-F125P. As a control, infection of 293 cells
demonstrated that each of these viruses is equally capable of
expressing DBP in the context of wild-type E1A.

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 6.
DBP accumulation correlates with E2F induction and virus
growth. HeLa cells and 293 cells were infected at a multiplicity of
infection of 200 virus particles per cell (~8 to 10 PFU/cell), and
cellular lysates were prepared 8, 16, and 24 h after infection for
HeLa cells and 16 h after infection for 293 cells. Fifty
micrograms of cellular extract was loaded per lane on an SDS-10%
polyacrylamide gel, electrophoresed, transferred to nitrocellulose, and
analyzed for DBP expression by Western blotting using an anti-DBP MAb
(31). The viruses used in the analysis were WT300,
dl356+E4-6/7-WT (Ad2 WT 6/7), and
dl356+E4-6/7-F125P (Ad2 F125P).
|
|
 |
DISCUSSION |
Previously it has been difficult to reconcile the conservation of
functional E4-6/7 proteins among Ads of evolutionarily divergent subgroups with the fact that this protein is not essential for virus
infection in cultured cells (33). The results presented in
this report directly correlate the ability of the E4-6/7 protein to
induce stable E2F DNA binding to the viral E2a promoter with increased
expression of E2 gene products and the production of infectious virus.
Furthermore, they indicate the importance that E2F induction by E4-6/7
might have an Ad infection under more stringent conditions of natural
infection. For example, the relative levels of viral proteins observed
in infections of cultured cells may not accurately reflect the levels
found in natural infection. If E1A levels were lower and E4 levels were
higher due to the relative activities of their respective promoter
regions, the ability of E4-6/7 to displace Rb protein family members
from E2Fs may be more essential for virus growth. Additionally, the
composition of E2F complexes in normal versus cultured cells may be
different: higher levels of higher-order E2F complexes may be found in
natural infection, whereas in cultured cells where free E2F activity
may be more abundant, reducing the need for Rb protein family
displacement from E2Fs. The ability of the E4-6/7 protein to displace
pRb and p107 from E2Fs in HeLa cells is entirely consistent with our
previous observation that the E4-6/7 protein and pRb bind to E2F-1 in a mutually exclusive manner in vitro, since both proteins require the
conserved marked box region of E2F-1 for stable protein interaction (28).
The fact that the levels of recombinant virus
dl356-E4-6/7-WT, which does not express functional E1A
proteins in infected cells, were not more than 50-fold lower than those
of wild-type Ad5 has several implications. First, the cumulative effect
of all other viral early gene products on productive infection in cells
in culture does not enhance virus growth more than 50-fold. One could
argue that the CMV promoter/enhancer driving expression of the E4-6/7
protein with this recombinant virus might allow expression of other
early viral genes, but this phenomenon does not appear to have had a
major effect in these assays. If it had, then one would anticipate that
activation of other early genes also would enhance growth of
dl356+E4-6/7-F125P (CMV enhancer positive) in comparison to
dl356+CAT (CMV enhancer negative), yet this was not the case
in HEL cells (Fig. 3B), and early gene activation at most contributed a
5- to 10-fold increase in virus growth in A549 (Fig. 3A) and HeLa (Fig.
2) cells, respectively. The 5- to 10-fold effect of expression of the
E4-6/7-F125P mutant protein on virus growth in HeLa and A549 cells may
reflect the ability of this protein to displace Rb protein family
members from E2Fs as was seen with the wild-type E4-6/7 product (Fig. 5). Thus, the Ad DNA replication proteins appear to play the major rate-limiting role for Ad infection in cultured cells.
Finally, several recent reports have noted that Ad E4 expression
enhances the duration of transgene expression in infected animals and
promotes viability of primary endothelial cells in culture (1, 3,
9, 20, 29, 37). It was noted that for these reasons, E4
expression may be beneficial for improving the utility of Ad gene
therapy vectors. The results presented here provide a caveat to
possible benefit, since the enforced expression of E4 in E1A-negative
recombinant Ad vectors may lead to unintended viral DNA replication due
to E4-6/7 expression. Thus, there is clearly the need to anticipate
that the expression of specific E4 gene products in recombinant Ad
vectors to enhance transgene expression may also have undesired
consequences for viral infection.
 |
ACKNOWLEDGMENTS |
We thank our colleagues for many helpful discussions, and we
thank Gia Feeney and Tina Philipsberg for excellent technical help. We
are grateful to David Spector for providing human embryonic lung cells.
This research was supported by Public Health Service grants CA28146 and
AI41636 from the National Institutes of Health to P.H. R.J.O. was
supported by NIH Training Grant CA09176.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Molecular Genetics and Microbiology, School of Medicine, State
University of New York, Stony Brook, NY 11794. Phone: (631) 632-8813. Fax: (631) 632-8891. E-mail:
phearing{at}ms.cc.sunysb.edu.
Present address: Department of Anatomy, Howard Hughes Medical
Institute, University of California, San Francisco, CA 94143.
 |
REFERENCES |
| 1.
|
Armentano, D.,
J. Zabner,
C. Sacks,
C. C. Sookdeo,
M. P. Smith,
J. A. St. George,
S. C. Wadsworth,
A. E. Smith, and R. J. Gregory.
1997.
Effect of the E4 region on the persistence of transgene expression from adenovirus vectors.
J. Virol.
71:2408-2416[Abstract].
|
| 2.
|
Boyer, T. G.,
M. E. Martin,
E. Lees,
R. P. Ricciardi, and A. J. Berk.
1999.
Mammalian Srb/Mediator complex is targeted by adenovirus E1A protein.
Nature
399:276-279[CrossRef][Medline].
|
| 3.
|
Brough, D. E.,
C. Hsu,
V. A. Kulesa,
G. M. Lee,
L. J. Cantolupo,
A. Lizonova, and I. Kovesdi.
1997.
Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo.
J. Virol.
71:9206-9213[Abstract].
|
| 4.
|
Cress, W. D., and J. R. Nevins.
1996.
Use of the E2F transcription factor by DNA tumor virus regulatory proteins.
Curr. Top. Microbiol. Immunol.
208:63-78[Medline].
|
| 5.
|
Dignam, J. D.,
R. M. Lebovitz, and R. G. Roeder.
1983.
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.
Nucleic Acids Res.
11:1475-1489[Abstract/Free Full Text].
|
| 6.
|
Dyson, N.
1998.
The regulation of E2F by pRB-family proteins.
Genes Dev.
12:2245-2262[Free Full Text].
|
| 7.
|
Feinberg, A. P., and B. Vogelstein.
1983.
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.
Anal. Biochem.
132:6-13[CrossRef][Medline].
|
| 8.
|
Flint, J., and T. Shenk.
1989.
Adenovirus E1A protein: paradigm viral transactivator.
Annu. Rev. Genet.
23:141-161[CrossRef][Medline].
|
| 9.
|
Gorziglia, M. I.,
C. Lapcevich,
S. Roy,
Q. Kang,
M. Kadan,
V. Wu,
P. Pechan, and M. Kaleko.
1999.
Generation of an adenovirus vector lacking E1, E2a, E3, and all of E4 except open reading frame 3.
J. Virol.
73:6048-6055[Abstract/Free Full Text].
|
| 10.
|
Graham, F. L.,
J. Smiley,
W. C. Russell, and R. Nairn.
1977.
Characteristics of a human cell line transformed by DNA from human adenovirus type 5.
J. Gen. Virol.
36:59-72[Abstract/Free Full Text].
|
| 11.
|
Halbert, D. N.,
J. R. Cutt, and T. Shenk.
1985.
Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff.
J. Virol.
56:250-257[Abstract/Free Full Text].
|
| 12.
|
Hardy, S.,
D. A. Engel, and T. Shenk.
1989.
An adenovirus early region 4 gene product is required for induction of the infection-specific form of cellular E2F activity.
Genes Dev.
3:1062-1074[Abstract/Free Full Text].
|
| 13.
|
Hardy, S., and T. Shenk.
1989.
E2F from adenovirus-infected cells binds cooperatively to DNA containing two properly oriented and spaced recognition sites.
Mol. Cell. Biol.
9:4495-4506[Abstract/Free Full Text].
|
| 14.
|
Harlow, E., and D. Lane.
1988.
Antibodies: a laboratory manual.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 15.
|
Huang, M.-M., and P. Hearing.
1989.
The adenovirus early region 4 open reading frame 6/7 protein regulates the DNA binding activity of the cellular transcription factor, E2F, through a direct complex.
Genes Dev.
3:1699-1710[Abstract/Free Full Text].
|
| 16.
|
Jones, N., and T. Shenk.
1979.
An adenovirus type 5 early gene function regulates expression of other early viral genes.
Proc. Natl. Acad. Sci. USA
76:3665-3669[Abstract/Free Full Text].
|
| 17.
|
Kovesdi, I.,
R. Reichel, and J. R. Nevins.
1986.
Identification of a cellular transcription factor involved in E1A trans-activation.
Cell
45:219-228[CrossRef][Medline].
|
| 18.
|
Lee, W. S.,
C. C. Kao,
G. O. Bryant,
X. Liu, and A. J. Berk.
1991.
Adenovirus E1A activation domain binds the basic repeat in the TATA box transcription factor.
Cell
67:365-376[CrossRef][Medline].
|
| 19.
|
Liu, F., and M. R. Green.
1994.
Promoter targeting by adenovirus E1A through interaction with different cellular DNA-binding domains.
Nature
368:520-525[CrossRef][Medline].
|
| 20.
|
Lusky, M.,
L. Grave,
A. Dieterlé,
D. Dreyer,
M. Christ,
C. Ziller,
P. Furstenberger,
J. Kintz,
D. Ali Hadji,
A. Pavirani, and M. Mehtali.
1999.
Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3.
J. Virol.
73:8308-8319[Abstract/Free Full Text].
|
| 21.
|
Manohar, C. F.,
J. Kratochvil, and B. Thimmapaya.
1990.
The adenovirus EII early promoter has multiple E1A-sensitive elements, two of which function cooperatively in basal and virus-induced transcription.
J. Virol.
64:2457-2466[Abstract/Free Full Text].
|
| 22.
|
Marton, M. J.,
S. B. Baim,
D. A. Ornelles, and T. Shenk.
1990.
The adenovirus E4 17-kilodalton protein complexes with the cellular transcription factor E2F, altering its DNA-binding properties and stimulating E1A-independent accumulation of E2 mRNA.
J. Virol.
64:2345-2359[Abstract/Free Full Text].
|
| 23.
|
Murthy, S. C. S.,
G. P. Bhat, and B. Thimmappaya.
1985.
Adenovirus EIIA early promoter: transcriptional control elements and induction by the viral pre-early E1A gene, which appears to be sequence independent.
Proc. Natl. Acad. Sci. USA
82:2230-2234[Abstract/Free Full Text].
|
| 24.
|
Neill, S. D.,
C. Hemstrom,
A. Virtanen, and J. R. Nevins.
1990.
An adenovirus E4 gene product trans-activates E2 transcription and stimulates stable E2F binding through a direct association with E2F.
Proc. Natl. Acad. Sci. USA
87:2008-2012[Abstract/Free Full Text].
|
| 25.
|
Neill, S. D., and J. R. Nevins.
1991.
Genetic analysis of the adenovirus E4 6/7 trans activator: interaction with E2F and induction of a stable DNA-protein complex are critical for activity.
J. Virol.
65:5364-5373[Abstract/Free Full Text].
|
| 26.
|
Obert, S.,
R. J. O'Connor,
S. Schmid, and P. Hearing.
1994.
The adenovirus E4-6/7 protein transactivates the E2 promoter by inducing dimerization of a heteromeric E2F complex.
Mol. Cell. Biol.
14:1333-1346[Abstract/Free Full Text].
|
| 27.
|
O'Connor, R. J., and P. Hearing.
1991.
The C-terminal 70 amino acids of the adenovirus E4-ORF6/7 protein are essential and sufficient for E2F complex formation.
Nucleic Acids Res.
19:6579-6586[Abstract/Free Full Text].
|
| 28.
|
O'Connor, R. J., and P. Hearing.
1994.
Mutually exclusive interaction of the adenovirus E4-6/7 protein and the retinoblastoma gene product with internal domains of E2F-1 and DP-1.
J. Virol.
68:6848-6862[Abstract/Free Full Text].
|
| 29.
|
Ramalingam, R.,
S. Rafii,
S. Worgall,
D. E. Brough, and R. G. Crystal.
1999.
E1( )E4(+) adenoviral gene transfer vectors function as a "pro-life" signal to promote survival of primary human endothelial cells.
Blood
93:2936-2944[Abstract/Free Full Text].
|
| 30.
|
Raychaudhuri, P.,
S. D. Bagchi,
S. Neill, and J. R. Nevins.
1990.
Activation of the E2F transcription factor in adenovirus-infected cells involves E1A-dependent stimulation of DNA-binding activity and induction of cooperative binding mediated by an E4 gene product.
J. Virol.
64:2702-2710[Abstract/Free Full Text].
|
| 31.
|
Reich, N. C.,
P. Sarnow,
E. Duprey, and A. J. Levine.
1983.
Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA binding protein.
Virology
128:480-484[CrossRef][Medline].
|
| 32.
|
Reichel, R.,
S. D. Neill,
I. Kovesdi,
M. C. Simon,
P. Raychaudhuri, and J. R. Nevins.
1989.
The adenovirus E4 gene, in addition to the E1A gene, is important for trans-activation of E2 transcription and for E2F activation.
J. Virol.
63:3643-3650[Abstract/Free Full Text].
|
| 33.
|
Schaley, J.,
R. J. O'Connor,
L. J. Taylor,
D. Bar-Sagi, and P. Hearing.
2000.
Induction of the cellular E2F-1 promoter by the adenovirus E4-6/7 protein.
J. Virol.
74:2084-2093[Abstract/Free Full Text].
|
| 34.
|
Schwarz, E.,
U. K. Freese,
L. Gissmann,
W. Mayer,
B. Roggenbuck,
A. Stremlau, and H. zur Hausen.
1985.
Structure and transcription of human papillomavirus sequences in cervical carcinoma cells.
Nature
314:111-114[CrossRef][Medline].
|
| 35.
|
Stow, N. D.
1981.
Cloning of a DNA fragment from the left-hand terminus of the adenovirus type 2 genome and its use in site-directed mutagenesis.
J. Virol.
37:171-180[Abstract/Free Full Text].
|
| 36.
|
Tommasino, M., and L. Crawford.
1995.
Human papillomavirus E6 and E7: proteins which deregulate the cell cycle.
Bioessays
17:509-518[CrossRef][Medline].
|
| 37.
|
Wang, Q.,
G. Greenburg,
D. Bunch,
D. Farson, and M. H. Finer.
1997.
Persistent transgene expression in mouse liver following in vivo gene transfer with a E1/ E4 adenovirus vector.
Gene Ther.
4:393-400[CrossRef][Medline].
|
| 38.
|
Wold, W. S. M.
1999.
Adenovirus methods and protocols.
Humana Press, Totowa, N.J.
|
Journal of Virology, July 2000, p. 5819-5824, Vol. 74, No. 13
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lockley, M., Fernandez, M., Wang, Y., Li, N. F., Conroy, S., Lemoine, N., McNeish, I.
(2006). Activity of the Adenoviral E1A Deletion Mutant dl922-947 in Ovarian Cancer: Comparison with E1A Wild-type Viruses, Bioluminescence Monitoring, and Intraperitoneal Delivery in Icodextrin. Cancer Res.
66: 989-998
[Abstract]
[Full Text]
-
Fang, L., Spindler, K. R.
(2005). E1A-CR3 Interaction-Dependent and -Independent Functions of mSur2 in Viral Replication of Early Region 1A Mutants of Mouse Adenovirus Type 1. J. Virol.
79: 3267-3276
[Abstract]
[Full Text]
-
Schaley, J. E., Polonskaia, M., Hearing, P.
(2005). The Adenovirus E4-6/7 Protein Directs Nuclear Localization of E2F-4 via an Arginine-Rich Motif. J. Virol.
79: 2301-2308
[Abstract]
[Full Text]
-
Fang, L., Stevens, J. L., Berk, A. J., Spindler, K. R.
(2004). Requirement of Sur2 for Efficient Replication of Mouse Adenovirus Type 1. J. Virol.
78: 12888-12900
[Abstract]
[Full Text]
-
Shepard, R. N., Ornelles, D. A.
(2004). Diverse Roles for E4orf3 at Late Times of Infection Revealed in an E1B 55-Kilodalton Protein Mutant Background. J. Virol.
78: 9924-9935
[Abstract]
[Full Text]
-
Shepard, R. N., Ornelles, D. A.
(2003). E4orf3 Is Necessary for Enhanced S-Phase Replication of Cell Cycle-Restricted Subgroup C Adenoviruses. J. Virol.
77: 8593-8595
[Abstract]
[Full Text]
-
Haviv, Y. S., Takayama, K., Glasgow, J. N., Blackwell, J. L., Wang, M., Lei, X., Curiel, D. T.
(2002). A Model System for the Design of Armed Replicating Adenoviruses Using p53 as a Candidate Transgene. Molecular Cancer Therapeutics
1: 321-328
[Abstract]
[Full Text]
-
Balague, C., Noya, F., Alemany, R., Chow, L. T., Curiel, D. T.
(2001). Human Papillomavirus E6E7-Mediated Adenovirus Cell Killing: Selectivity of Mutant Adenovirus Replication in Organotypic Cultures of Human Keratinocytes. J. Virol.
75: 7602-7611
[Abstract]
[Full Text]